ANO1 and cystic fibrosis: In CF, TMEM16A and its regulator CLCA1 have been proposed as potential drug targets to compensate for the abrogated CFTR function in CF patients, while in asthma it may help to solubilize excess inflammatory mucus which may otherwise lead to airway obstruction9,10.